Now, adjusted diluted net earnings per common share were $2.39 and were up 39% compared to 2020 and we generated $1.7 billion of free cash flow in the quarter, bringing our year-to-date total to $5.2 billion, which is up 46.5% year-over-year.
Reported revenue was up 7% with core revenue up 7.5%. Our sales were $7.2 billion and we delivered 20.5% core revenue growth with portfoliowide strength led by Diagnostics and Life Sciences.
We expect to deliver fourth quarter core revenue growth in the low to mid teens range, with high single-digit core revenue growth in our base business and a mid to high single-digit core growth contribution from COVID-related revenue tailwind.
Our team delivered another outstanding results in our third quarter with over 20% core revenue growth, nearly 40% adjusted earnings-per-share growth and strong free cash flow generation.
Geographically, high growth markets grew approximately 25% and developed markets were up nearly 20%.
In fact, revenue in each of our three largest markets, North America, Western Europe and China was up approximately 20% or more in the quarter.
Life Sciences reported revenue increased 24.5% with core revenue up 20%.
COVID-only tests accounted for approximately 80% of those shipments and our 4-in-1 combination tests for COVID-19 Flu-A and B and RSV represented approximately 20%.
Now for the full year 2021, we now expect to deliver more than 20% core tailwind and our base business will each contribute more than 10% to our 2021 core revenue growth rate.
